1997
DOI: 10.1002/(sici)1097-0215(19970502)71:3<429::aid-ijc21>3.0.co;2-9
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: CD22 antibodies (Abs) bound to B-cell lymphomas are known to be internalized and catabolized rapidly. Therefore, it would be expected that use of CD22 as a target for radioimmunotherapy should be enhanced by the use of ''residualizing'' radiolabels, which are trapped within the cell after catabolism of the Ab to which they had been conjugated. Our study was intended to evaluate this hypothesis using Ab LL2. In initial experiments, we found that LL2 binding was strongly temperature dependent, with approximately… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

4
12
1

Year Published

2000
2000
2011
2011

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 22 publications
(17 citation statements)
references
References 10 publications
4
12
1
Order By: Relevance
“…12 This study also indicated that tumor uptake of yttrium-and lutetium-labeled hLL2 is higher when compared to 131 I-and 186 Re-labeled hLL2. In a previous study, tumor uptake of the radioiodinated hLL2 did not exceed that of the nonspecific control antibody in a mouse lymphoma model, 17 but the present study shows a significant difference in tumor uptake of radioiodinated hLL2 over radioiodinated cG250. In vivo, 131 I-labeled hLL2 is rapidly catabolized within the lysosomes after internalization by the tumor cell.…”
Section: Discussioncontrasting
confidence: 83%
“…12 This study also indicated that tumor uptake of yttrium-and lutetium-labeled hLL2 is higher when compared to 131 I-and 186 Re-labeled hLL2. In a previous study, tumor uptake of the radioiodinated hLL2 did not exceed that of the nonspecific control antibody in a mouse lymphoma model, 17 but the present study shows a significant difference in tumor uptake of radioiodinated hLL2 over radioiodinated cG250. In vivo, 131 I-labeled hLL2 is rapidly catabolized within the lysosomes after internalization by the tumor cell.…”
Section: Discussioncontrasting
confidence: 83%
“…It is interesting to note that the same is true for the radiolabeled Abs to CD20 that were developed into Zevalin and Bexxar, with remarkably little published evidence of effective therapy with radiolabeled anti-CD20 in mouse model systems (26 -28). 90 Y-epratuzumab was shown to localize specifically to tumor xenografts, although at relatively low levels (29), and the same is true of anti-CD20 Abs (23). In the case of anti-CD20 Abs, the strong therapeutic effect of the unconjugated Ab in the model used by Buchsbaum et al (30) may have obscured any effect of the radiolabel.…”
Section: Discussionmentioning
confidence: 99%
“…Another possibility is that the unconjugated anti-CD20 Ab induced a higher level of expression of the CD22 antigen, as was suggested by previous in vitro studies (5), but our Ab localization studies did not support this possibility. The specificity of epratuzumab (hLL2) uptake in Ramos tumors was established previously (29). The mechanism of action of unconjugated anti-CD20 IgG alone has been investigated in many experimental models (1,2,13,33,34), and seems to require one or more accessory factors, such as various effector cells (acting via Ab-dependent cellular cytotoxicity), complement, and/or the production of chemokines by the Ab-treated tumor (13).…”
Section: Discussionmentioning
confidence: 99%
“…Direct radio-iodination occurring with extant tyrosine moieties of the protein has dominated this field. The convenience of this method, however, is compromised by potentially rapid de-iodination of the protein postinternalization, a characteristic that is lacking when radiometals are used 8,9 . 90 Y has a pure β --emission that delivers ~4.5 times more radiation per mCi to a tumour than does 131 I.…”
Section: Diane E Milenic Erik D Brady and Martin W Brechbielmentioning
confidence: 99%